These enrichment-based next-generation sequencing (NGS) reagents enable simultaneous analysis of DNA and RNA, and can cover a wide range of cancer variant types. This methodology provides laboratories with a deep view into the genetics of cancer.
Analysis of TruSight Oncology 500 data with PierianDx Clinical Genomics Workspace Software
Brochure | PDF < 1 MB
TruSight Oncology 500 Demo Program Flyer
Brochure | PDF < 1 MB
Analysis of TMB and MSI Status with TruSight Oncology 500
Application Note | HTML
Optimizing RNA input to detect gene fusions with TruSight Oncology 500 High-Throughput
Technical Note | PDF < 1 MB
TruSight Tumor 170 Support Documentation
All TruSight Oncology UMI Reagents Support All TruSight Tumor 170 Support